Clario celebrates over 50 years of innovation and expertise in clinical trials for Clinical Trials Day 

Clinical trials are the foundation of all advances in modern medicine. This year’s Clinical Trials Day is an opportunity to reflect on Clario’s impact on clinical trials. 

• Founded in 1972 to offer scientists innovative technologies for more efficient and accurate data collection and analysis in clinical trials, Clario has now supported more than 27,000 clinical studies involving more than seven million patients in over 100 countries, higher than any similar company.
• Clario’s scientists are at the forefront of their fields and their collective scientific and regulatory expertise has contributed to over 500 FDA and EMEA new drug approvals.
• Preparing for the future, Clario is currently investing in the production of over 30 AI solutions to deliver faster and more accurate results for researchers. 

PHILADELPHIA, PA – May 19, 2023 – Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, is proud to reflect on its 50-year impact on the advancement of clinical research through innovative technology and extensive scientific and regulatory expertise. 

International Clinical Trials Day is celebrated annually on May 20 to celebrate the first randomized clinical trial recorded on May 20, 1747, by a British Royal Navy surgeon James Lind. Lind’s innovative controlled study method paved the way for clinical trials today. This year’s Clinical Trials Day is an opportunity for Clario to celebrate its scientists who have supported more than 40 clinical studies every month since it was founded in 1972. Their story of dedication, scientific rigor and regulatory expertise has helped sponsors achieve more than 500 new drug approvals by the FDA and EMEA. 

“On this year’s Clinical Trials Day, we want to honor our scientists for their dedication to advancing our mission to unlock better evidence and transform lives by supporting clinical research, addressing widely unmet medical needs,” said Todd Rudo M.D., Chief Medical Officer, Clario. “Clario’s 50 years of experience in clinical trial data management is a true differentiator, enabling our scientific team to have unique insight into customer needs and allowing us to partner with sponsors in selecting the best technologies to meet their objectives. Our drive for innovation is founded on continuously improving our endpoint collection technologies, increasing accuracy while minimizing patient and site burden, to help sponsors most accurately characterize the safety and efficacy of their medicine.” 

For over 50 years, Clario has led the way in developing innovative data collection technologies to help researchers understand the safety and efficacy of new medicines and how they could best help patients. 

Clario’s extensive expertise keeps them at the forefront of endpoint technology solutions with deep knowledge of the regulatory landscape, study designs and endpoint selection. Twenty-five years ago, Clario launched its first remote data collection technology – a Holter monitor for continuous ECG collection in a clinical study outside of the clinic. Evolving further with the increased adoption of hybrid and decentralized clinical trials, and more recently with the COVID-19 pandemic, Clario has since launched many additional technologies for at-home data collection. Clario also sponsored the pivotal IQ-CSRC study, which demonstrated the efficacy of exposure-response modeling of phase I ECG data as a potential replacement for a dedicated Thorough QT (TQT) study, and directly contributed to subsequent revisions of the ICH E14 regulatory guideline, applicable globally. Finally, with recent advancements in artificial intelligence (AI), Clario has implemented over 30 AI tools in recent years to enhance scientists’ abilities to be more efficient and accurate in clinical trial data endpoint analysis.